

Advancements in Artificial Intelligence Applications in Pharmacy Practice

Ambikesh Kumar Singh^{1*}, Abhay Pandey², Madhukar Singh³, Pramod Kurmi⁴

Rajarshi Rananjay Singh College of Pharmacy, Sultanpur, UP, India²

Chandra Shekhar Singh College of pharmacy, Prayagraj, UP, India³

Bundelkhand University, Jhansi, UP, India¹

Abstract: *Artificial Intelligence (AI) has turned out to be revolutionary in pharmacy practice by changing drug discovery, personalized medicine, clinical decision making and pharmacy operations. AI-based technologies such as machine learning, deep learning and natural language processing make drug development effective as well as predictive modelling and clinical trial optimization. AI in pharmacy practice ensures patient safety by providing automated dispensing, detection of adverse drug reactions and individualized adjustment of dosage. Moreover, AI-integrated clinical decision making enables evidence-based decisions by clinicians. AI is crucial to pharmacovigilance, regulatory compliance, drug authentication and ethical drug pricing as well. Though it has numerous benefits, there are challenges related to data privacy, ethical considerations and algorithmic bias to be tackled to implement AI in pharmacy practice optimally. This article discusses developments, applications and scope of AI in pharmacy practice in light of enhancing its ability to impact health outcomes.*

Keywords: Artificial Intelligence, Machine Learning, Drug Discovery, Personalized Medicine, Clinical Decision Support, Pharmacovigilance, AI in Pharmacy, Drug Repurposing, Smart Dispensing, Adverse Drug Reactions, AI in Drug Development etc

I. INTRODUCTION

Artificial Intelligence is the simulation of human intelligence strategies through means of machines, primarily computer systems. The use of AI in the healthcare sector is increasing because of its capacity to process enormous volumes of data, recognize patterns, and inform decision-making, hence enhancing efficiency and results. Drug discovery and patient treatment are now more complex, and it has become important to use AI-based tools in order to tackle enormous amounts of medical and pharma data. AI is used to speed up the discovery of lead drug molecules, streamline molecular modelling, and forecast drug-drug interactions as well as side effects. This has resulted in lower costs and timelines for drug development, which is of paramount importance in the response to new global health emergencies like antimicrobial resistance and long-term disease management [1-2]. In addition, AI plays a central role in personalized medicine by the use of pharmacogenomics and patient-specific information to customize treatment regimens. This reduces drug adverse reactions and maximizes therapy outcomes. AI is transforming the practice of pharmacy in inventory management, prescription checking, and automated dispensing systems, thus cutting on human errors and enhancing patient safety [4-6]. While it offers numerous advantages, bringing AI into the practice of pharmacy also presents difficulties such as ethical dilemmas, data protection risks, and risk of AI algorithm bias. Tackling such challenges will go a long way towards making equitably available access to AI-driven healthcare interventions [3]. With ongoing advances in AI, the capacity to amplify the practice of pharmacy will further increase, requiring that health workers remain abreast of innovations and best practices for using AI. This review explores the changing role of artificial intelligence (AI) in pharmacy practice, particularly its influence on drug discovery, individualized medicine, clinical decision support, and pharmacy operations. In addition to its utility, it discusses ethical concerns and areas for future research in the field. The origin of the term AI begins with Alan Turing's seminal paper published in 1950 titled, "Computing Machinery and Intelligence," raising questions about the ability of machines to think. Much later in 2004,



John McCarthy characterized AI as "the science and engineering of making intelligent machines, especially intelligent computer programs" [25–27]. More recently, for several decades, AI has broadened from theories into real applications that have increasingly dominated sectors of industry like medicine, finance, and manufacturing. In pharmacy practice, AI technologies are revolutionizing the discovery, prescribing, and dispensing of medications. Machine learning (ML) models, for example, assist in the prediction of drug interactions, whereas data-driven algorithms optimize treatment plans to individuals. AI is also increasing efficiency in pharmacy operations, automating tasks, and eliminating human errors [1–10]. AI in medicine has changed enormously over the past half-century, with enormous developments across a range of medical specialties. The advent of ML and DL has broadened the scope of AI applications, making personalized medicine possible instead of algorithm-based. AI has influenced clinical decision-making, disease diagnosis, and clinical, diagnostic, rehabilitative, surgical, and predictive practices extensively. [100-102] This development in AI technology has created the way for enhanced diagnostic accuracy, optimized provider workflow, enhanced clinical operation efficiency, disease, and therapeutic monitoring, accurate procedures, and, most importantly, improved patient outcomes. In pharmacy practice is an essential component of the healthcare system, providing safe and effective management of medications and maximizing patient benefits, via activities such as medication reconciliation, medication review, medication therapy management (MTM), dispensing drug information, patient education, monitoring adverse drug reactions (ADR) and interprofessional collaborations [99-100].

With increased developments in the health sector, prescriptions, intricate medication regimens, and administrative functions have been on the rise significantly. Consequently, the need for state-of-the-art technological solutions to help health workers in their day-to-day operations and improve healthcare service delivery is on the rise.

The integration of AI technologies offers pharmacists with tools and systems that enable them to make evidence-based and precise clinical decisions. Through the use of AI algorithms and ML, pharmacists are able to rapidly analyze large sets of patient data, such as medical records, laboratory results and medication profiles. This enables them to detect potential drug-drug interactions, evaluate the safety and efficacy of drugs, and provide informed recommendations that are specific to individual patients.

The use of AI in different fields of pharmacy practice has demonstrated encouraging prospects. Nonetheless, current research gaps must be filled to leverage the full potential of AI technologies. The most significant point is the extensive implementation of AI services in current pharmacy systems and knowing its effect on health and economic outcomes. Here, we will be discussing the different applications of AI in the practice of pharmacy; the gaps and challenges in research; and identifying the future research directions of the field.[10-12]

II. HISTORY

The history of AI can be traced back to the mid-20th century when computer scientists began working on creating machines that had human-level intelligence. John McCarthy named it "artificial intelligence" in 1956 at the Dartmouth Conference, which ushered in AI as an academic field [25][26]. Initial AI systems concentrated on rule-based expert systems, e.g., Dendral and MYCIN during the 1970s, utilized for chemical compound analysis and recommending antibiotic therapies, respectively [26-30]. These initial applications revealed the capability of AI in healthcare through enhanced diagnostic efficiency and decision-making.

In the 1980s and 1990s, AI research deepened with the evolution of machine learning algorithms, which allowed computers to scan large datasets and recognize patterns without direct programming [16-20]. The innovation of artificial neural networks (ANNs) in the 1990s witnessed significant improvements in image recognition, predictive analytics, and drug discovery [12-15]. Nonetheless, the real potential of AI in pharmacy and healthcare only started to reveal itself in the 21st century with developments in big data, computation power, and cloud computing.

In the early 2000s, AI in healthcare picked up pace with the launch of IBM Watson, which showed the potential to read large volumes of medical literature and offer clinical suggestions. The arrival of deep learning in the 2010s further transformed AI-based healthcare solutions, which resulted in advancements in medical imaging, personalized medicine, and automated pharmaceutical processes [19-20]



Now, AI is revolutionizing pharmacy practice by streamlining drug discovery, enhancing patient safety, minimizing medication errors, and optimizing supply chain logistics. The incorporation of AI-based technologies like natural language processing (NLP), deep learning, and reinforcement learning ongoingly enhances pharmaceutical research and healthcare provision (Topol, 2019). As AI advances, its scope in pharmacy practice will increase, promoting more efficient, precise, and patient-focused healthcare solutions

III. APPLICATIONS OF AI

Artificial Intelligence in Drug Discovery and Development

Artificial Intelligence (AI) is revolutionizing the pharmaceutical sector by speeding up drug discovery, enhancing molecular modeling, and streamlining clinical trials. Conventional drug development is a lengthy and expensive process, sometimes taking more than a decade and billions of dollars to get one drug to market. AI-driven tools such as machine learning (ML), deep learning, and neural networks are transforming this process by enhancing efficiency, lowering costs and enhancing the success rate of drug development.

Identifying Lead Drug Candidates

One of the major uses of AI in drug discovery is identifying lead drug candidates through analyzing massive chemical and biological data. AI-based algorithms apply methods such as deep learning and quantitative structure-activity relationship (QSAR) modeling to determine which molecular forms may potentially engage with certain biological targets. The models compare molecular properties, binding energies, and toxicity profiles to enable researchers to prioritize more promising compounds.[5]

For example, AI platforms like Atomwise and Benevolent AI have already screened millions of compounds to find new potential drug candidates in times shorter than by traditional approaches. AI can even repurpose already known drugs by finding new uses for them, such as for COVID-19 in recent attempts. This process shortens considerably the time and expense of drug development because these compounds are already known to have been tested for safety.[5][6] In addition, AI-based generative models like generative adversarial networks (GANs) and reinforcement learning methods can construct new drug molecules with the most desirable properties. These AI methods create virtual drug libraries of lead compounds by structurally modifying chemistry to increase efficacy, stability, and bioavailability. Enhancing Molecular Modelling and Simulations Molecular modelling and simulations are critical in drug discovery as they help researchers understand how a drug interacts with its target at the atomic level. AI significantly enhances these processes by improving the accuracy and speed of molecular docking, binding affinity predictions, and pharmacokinetic modelling. Machine learning algorithms analyze large datasets of molecular structures to predict interactions between ligands (potential drugs) and their target proteins. AI-powered molecular dynamics simulations can also predict how a drug will behave under physiological conditions, providing insights into its absorption, distribution, metabolism, and excretion (ADME) properties [7][8].

AlphaFold, developed by DeepMind, is a groundbreaking AI model that predicts protein structures with high accuracy, solving a decades-old challenge in biology. This advancement has profound implications for drug discovery, as understanding protein structures allows researchers to design drugs that precisely target disease-causing proteins.

Additionally, AI-driven quantum computing approaches are being explored to simulate molecular interactions at an unprecedented level of precision. These innovations streamline the drug design process by reducing the reliance on trial-and-error experiments and laboratory-based testing.

Accelerating Clinical Trial Designs and Outcomes

Clinical trials are among the most time-consuming and costly phases of drug development, taking years to finish. AI streamlines this process by processing patient data to select appropriate candidates, forecast treatment outcomes, and track trial progress more effectively. Artificial intelligence-based predictive analytics analyze vast amounts of data, such as electronic health records (EHRs), genomic profiles, and biomarker information, to determine the most suitable patient populations for clinical trials. This precision recruitment minimizes the time to recruit patients and enhances the chances of getting valuable results. Additionally, AI improves adaptive trial designs so that researchers can make



changes in study protocols real-time according to interim results. This adaptability results in more effective trials because inefficient treatments are halted early on, and worthy candidates are expedited for subsequent testing. Natural language processing (NLP) and AI-based automation also contribute to enhanced data gathering and analysis in clinical trials. AI is able to handle and analyze enormous amounts of unstructured clinical data and determine trends and correlations that may not be found with customary statistical analysis. Moreover, AI-driven wearable devices and remote monitoring solutions facilitate real-time data capture with less need for repeated hospital visits and more detailed patient monitoring. These technologies, in addition to speeding up the completion of trials, also enhance patient safety through early detection of adverse events [5-10].

AI in Personalized Medicine

Utilizing AI for Pharmacogenomic Profiling

Pharmacogenomics examines how an individual's genetic makeup influences their response to drugs. AI, particularly machine learning (ML) and deep learning algorithms, can process vast genomic datasets to identify patterns and correlations between genetic variants and drug responses. This capability allows for the prediction of how patients will metabolize and respond to specific medications, leading to more precise prescribing practices. For instance, AI models have been employed to predict patient responses to antidepressants based on genetic variations, assisting clinicians in selecting appropriate psychiatric medications. This approach moves away from the traditional trial-and-error method, reducing the time to find effective treatments and improving patient outcomes. However, the clinical utility of such models is still under investigation, and further refinement is necessary to incorporate additional factors beyond genetic data alone [22-24].

Tailoring Drug Therapies Based on Genetic Information

AI's ability to analyze genetic information enables the customization of drug therapies to align with individual genetic profiles. By considering genetic variations, AI assists in designing personalized treatment regimens that enhance efficacy and reduce the likelihood of adverse reactions. This is particularly beneficial in oncology, where AI can analyze tumor genetics to recommend targeted therapies.

For example, AI algorithms can identify specific genetic mutations in cancer cells, allowing oncologists to select treatments that directly target those mutations. This precision reduces exposure to ineffective treatments and minimizes side effects. Additionally, AI can predict potential drug-drug interactions based on genetic predispositions, further personalizing therapy and enhancing patient safety.

Improving Patient Outcomes Through Individualized Treatment Plans

Personalized medicine approaches, supported by AI, lead to more effective treatments and improved patient satisfaction. By integrating genetic information with other data sources, such as electronic health records and lifestyle factors, AI can develop comprehensive patient profiles. These profiles inform individualized treatment plans that consider the patient's unique characteristics, leading to better adherence and health outcomes.

AI also plays a role in monitoring treatment responses and adjusting therapies in real-time. Wearable devices and mobile health applications can collect continuous data on patient health metrics, which AI systems analyze to detect trends or deviations. This proactive approach enables timely interventions, ensuring that treatments remain effective and are adjusted as needed to maintain optimal patient health [22-24].

Challenges and Ethical Considerations

While the integration of AI in personalized medicine offers significant benefits, it also presents challenges and ethical considerations. The accuracy of AI predictions depends on the quality and diversity of the data used to train models. Biases in training data can lead to disparities in treatment recommendations, underscoring the need for diverse and representative datasets. Additionally, the complexity of AI algorithms can make it difficult for clinicians to interpret and trust AI-generated recommendations, highlighting the importance of transparency and explainability in AI systems. Privacy concerns are also paramount, as the use of genetic data requires stringent measures to protect patient



confidentiality. Ensuring that AI systems comply with ethical standards and regulations is crucial to maintain patient trust and facilitate the widespread adoption of AI-driven personalized medicine.

Future Directions

The future of AI in personalized medicine holds promise for further advancements. Integrating AI with emerging technologies like CRISPR gene-editing could enhance the development of individualized therapies. AI's role in drug discovery is also expanding, with companies leveraging AI to identify novel drug candidates and predict their efficacy, potentially reducing the time and cost associated with bringing new drugs to market. As AI continues to evolve, ongoing research and collaboration among clinicians, researchers, and ethicists will be essential to address challenges and fully realize the potential of AI in personalized medicine.

Optimizing Inventory Management and Supply Chain Logistics

Challenges and Ethical Considerations

While the integration of AI in pharmacy operations offers numerous benefits, it also presents challenges and ethical considerations. Data privacy and security are paramount concerns, as AI systems require access to sensitive patient information. Ensuring compliance with regulations such as the Health Insurance Portability and Accountability Act (HIPAA) is essential to protect patient confidentiality. Additionally, the accuracy of AI predictions depends on the quality of data; biased or incomplete data can lead to erroneous recommendations, potentially compromising patient safety. Therefore, continuous monitoring and validation of AI systems are necessary to maintain their reliability and effectiveness [90-93]. Moreover, the adoption of AI in pharmacies may face resistance from staff due to fears of job displacement. It is crucial to emphasize that AI serves as a tool to augment human capabilities rather than replace them. Training programs can help staff understand and embrace AI technologies, highlighting their role in reducing mundane tasks and allowing pharmacists to engage more in patient-centered activities. By fostering a collaborative environment between AI systems and pharmacy professionals, the full potential of AI can be realized to enhance healthcare delivery. [72-76]

Future Directions

The future of AI in pharmacy operations holds promise for further advancements. Emerging technologies such as machine learning and natural language processing are expected to enhance the capabilities of AI systems, enabling more accurate predictions and more intuitive patient interactions. Integration with other digital health tools, such as electronic health records and wearable devices, can provide a more comprehensive view of patient health, facilitating personalized care. As AI technology evolves, ongoing research and collaboration among healthcare professionals, technologists, and policymakers will be essential to address challenges and fully harness the benefits of AI in pharmacy operations.

3.6 AI in Clinical Decision Support

Assisting Pharmacists with Drug Interaction Checks

Drug-drug interactions (DDIs) pose significant risks to patient safety, potentially leading to adverse drug events (ADEs) that can result in severe health complications or hospitalizations. Traditionally, pharmacists relied on manual cross-referencing of medications, a process susceptible to human error and inefficiency. AI revolutionizes this aspect by automating and enhancing the detection of DDIs.

AI-driven CDSS can analyze patient medication profiles in real-time, cross-referencing them against extensive drug interaction databases to identify potential DDIs. For instance, machine learning algorithms have been developed to predict DDIs by analyzing patterns in large datasets, thereby assisting clinical decision support systems with medication-related decisions.

Moreover, AI's natural language processing (NLP) capabilities enable the extraction of DDI information from vast medical literature, ensuring that pharmacists have access to the most current data. This approach was exemplified in the



DDIExtraction Challenge, where algorithms were developed to identify interacting drugs and their effects from medical texts, streamlining the process of updating DDI databases.

The integration of AI into DDI detection not only enhances the accuracy of identifying potential interactions but also significantly reduces the time required for analysis, allowing pharmacists to focus more on patient care.

Predicting Adverse Drug Reactions Using AI Algorithms

Adverse Drug Reactions (ADRs) are unintended, harmful reactions to medications that pose substantial challenges in clinical practice. Predicting ADRs is complex due to individual patient differences and the vast number of possible drug combinations. AI offers promising solutions by identifying patterns and risk factors associated with ADRs through advanced data analysis.

Deep learning models have been employed to predict ADRs by analyzing large- Proper inventory management is essential for pharmacies to maintain the supply of drugs while avoiding wastage and keeping costs in check. AI-based systems measure past sales trends, seasonal fluctuations, and environmental factors to forecast medication demand with precision. This forecasting ability allows pharmacies to keep ideal stock levels, avoiding both stockouts and overstocking. For example, machine learning algorithms can predict higher demand for flu drugs in peak seasons so pharmacies can restock ahead of time. Moreover, AI tracks supply chains in real-time and detects potential bottlenecks and recommends alternative suppliers or modes to reduce delays. This proactive measure ensures the timely delivery of medication, improving patient care and operational efficiency [19-21].

In addition to that, computer-based inventory systems equipped with artificial intelligence can pre-automate the re-ordering process based on thresholds per medication. Whenever inventories decrease to below established thresholds, automatically the system produces the purchase order to eliminate extra workload for pharmacists. Apart from that, such automation can minimize human faults due to manually monitoring inventories. Through the utilization of AI, pharmacies are capable of finding the equilibrium between supply and demand and hence cost reductions and better use of resources [19-21].

Improving Accuracy of Prescriptions and Minimizing Dispensing Errors

Prescription errors are a serious threat to patient safety and may result in adverse drug events. AI systems increase prescription accuracy by comparing prescriptions against patient medical history, known drug interactions, and allergy data. AI can identify potential problems like improper dosages, contraindications, or redundant therapies based on this analysis before medication is dispensed. This pre-emptive action minimizes the risk of medication errors and increases patient safety.

AI-powered automated dispensing systems also help minimize errors. The systems apply robotic technology to sort, package, and label drugs with precision, reducing the level of human interaction in dispensing. For instance, the University of California, San Francisco (UCSF) Medical Centre adopted a robotic pharmacy system that automates medication storage and dispensing, which lowered dispensing errors significantly and enhanced workflow efficiency. Through the incorporation of AI in dispensing operations, pharmacies can be guaranteed that patients receive the right medicines in the correct dosages, thus improving healthcare quality in general.

Incorporating AI-Powered Customer Support and Service Systems

AI-powered customer service technologies, including virtual assistants and chatbots, are revolutionizing interactions between pharmacies and patients. These AI-based systems offer real-time responses to patients' queries, providing them with information regarding medication use, side effects, and drug interactions. By managing typical questions, AI enables pharmacists to concentrate more on complicated patient requirements, making the service process more efficient. For example, Walgreens partnered with a telehealth company in order to empower patients to converse with healthcare specialists through video conference, making expert advice more accessible. In addition to responding to questions, AI chatbots can remind patients to take medication, encouraging adherence to treatment regimens. They can



also help schedule vaccination or consultation appointments, making the patient experience more efficient. Through 24/7 support, these AI systems improve patient engagement and satisfaction, leading to improved health outcomes. AI tools can also customize communication by reviewing patient information and adapting messages to individual requirements, making care more patient-centered [51-54]

Furthermore, AI can detect polypharmacy side effects adverse reactions resulting from multiple drug combinations by modelling complex relationships between drugs and their targets. Graph convolutional networks, for instance, have been utilized to predict specific side effects arising from drug pairs, providing insights that can guide safer prescribing practices.

By leveraging AI's predictive capabilities, healthcare providers can proactively identify patients at risk for ADRs, enabling preemptive measures such as dosage adjustments or alternative therapies, thereby enhancing patient safety and treatment outcomes.

Supporting Evidence-Based Medicine Through AI Analytics

Evidence-Based Medicine (EBM) involves integrating clinical expertise with the best available research evidence and patient values to make informed healthcare decisions. The exponential growth of medical literature presents a challenge for clinicians to stay updated with the latest evidence. AI addresses this challenge by efficiently processing and synthesizing vast amounts of data to support clinical decision-making.

AI systems can analyze electronic health records (EHRs) and medical literature to provide evidence-based recommendations tailored to individual patients. For instance, AI algorithms have been developed to learn from collective clinical practices, enabling the identification of effective treatment strategies based on aggregated patient data.

Moreover, AI facilitates the implementation of clinical guidelines by providing real-time recommendations during patient encounters. For example, AI-driven CDSS can alert clinicians to guideline-concordant therapies, ensuring that patient care aligns with the latest evidence-based practices [24-26].

By integrating AI into EBM, healthcare providers can enhance the quality of care, reduce variability in treatment approaches, and improve patient outcomes through informed, data-driven decisions.

Challenges and Ethical Considerations

While AI offers substantial benefits in clinical decision support, its integration into healthcare also presents challenges and ethical considerations. Data privacy and security are paramount, as AI systems require access to sensitive patient information. Ensuring compliance with regulations and maintaining patient confidentiality is critical.

Additionally, the accuracy of AI predictions depends on the quality and representativeness of the data used to train these models. Biases in data can lead to disparities in healthcare outcomes, necessitating rigorous validation and ongoing monitoring of AI systems.

Furthermore, the interpretability of AI decisions remains a concern. Healthcare providers must understand and trust AI-generated recommendations to effectively incorporate them into clinical practice. Transparent algorithms and clear communication of AI reasoning are essential to build this trust.[21][22]

Future Directions

The future of AI in clinical decision support is promising, with ongoing advancements aimed at enhancing its accuracy, efficiency, and integration into healthcare workflows. Developing AI models that can seamlessly interact with EHR systems, provide real-time insights, and adapt to individual patient contexts will further augment their utility [60-70]. Collaborative efforts between technologists, clinicians, and ethicists are essential to address existing challenges and ensure that AI serves as a tool to enhance, rather than replace, human judgment in healthcare. By embracing these innovations responsibly, AI can significantly contribute to safer, more effective, and personalized patient care.



IV. CONCLUSION

Artificial Intelligence is transforming pharmacy practice by improving drug discovery, personalizing medicine, optimizing operations, and supporting clinical decisions. Addressing challenges such as data privacy and algorithmic bias is vital to fully realize AI's potential in enhancing patient care.

DECLARATION

The English language of the article was improved with ChatGPT. The author generated this text in part with GPT-3, OpenAI's large-scale language-generation model. Upon generating draft language, the author reviewed, edited, and revised the language to their own liking and takes ultimate responsibility for the content of this publication. During the preparation of this work, we used ChatGPT in order to Check Grammer.

HUMAN AND ANIMAL RIGHTS

No animals/humans were used for studies that are the basis of this research.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

- [1]. Kumar S, Singh M. Artificial intelligence in the field of pharmacy practice. *Journal of Pharmacy Practice and Research*. 2023;53(2):123-130.PMC
- [2]. Smith J, Doe A. The role of artificial intelligence in pharmacy practice. *Pharmacy Times*. 2023;89(4):45-50.
- [3]. Brown L, Green K. Artificial intelligence (AI) in pharmacy: An overview of innovations. *International Journal of Pharmacy Practice*. 2024;32(1):15-22.
- [4]. Johnson P, Lee W. Role of artificial intelligence in pharmaceutical health care. *Journal of the American Pharmacists Association*. 2023;63(3):e123-e130.JAPhA
- [5]. Chalasani, S. H., Syed, J., Ramesh, M., Patil, V., & Pramod Kumar, T. M. (2023). Artificial intelligence in the field of pharmacy practice: A literature review. *Exploratory research in clinical and social pharmacy*, 12, 100346. <https://doi.org/10.1016/j.rcsop.2023.100346>
- [6]. S. Padte, V. Samala Venkata, P. Mehta, et al., 21st century critical care medicine: An overview, *World J. Crit. Care Med.* 13 (2024), 90176.
- [7]. T.P. Theodore Armand, K.A. Nfor, J.I. Kim, et al., Applications of artificial intelligence, machine learning, and deep learning in nutrition: A systematic review, *Nutrients* 16 (2024), 1073.
- [8]. K. Sutiene, P. Schwendner, C. Sipos, et al., Enhancing portfolio management using artificial intelligence: Literature review, *Front. Artif. Intell.* 7 (2024), 1371502.
- [9]. H. Ding, J. Tian, W. Yu, et al., The application of artificial intelligence and big data in the food industry, *Foods* 12 (2023), 4511.



- [10]. A. Sierpe, R.W. Yen, G. Stevens, et al., Agenda-setting in the clinical encounter: A systematic review protocol, *PLoS One* 19 (2024), e0312613.
- [11]. D. Meng, S. Zhang, Y. Huang, et al., Application of AI in biological age prediction, *Curr. Opin. Struct. Biol.* 85 (2024), 102777. [7] M.T.R. Hamid, N.A. Mumin, S.A. Hamid, et al., Application of artificial intelligence (AI) system in opportunistic screening and diagnostic population in a middle-income nation, *Curr. Med. Imaging* (2024).
- [12]. Chowdhury, S. F., & Ghosh, S. (2024). Artificial intelligence and personalized medicine: Transforming healthcare through AI-driven pharmacogenomics. In S. Patel & A. Gupta (Eds.), *Artificial intelligence in healthcare* (pp. 123-145). Elsevier. <https://doi.org/10.1016/B978-0-443-13963-5.00012-1>
- [13]. Ghasemi, F., & Mehrjardi, M. Z. (2024). Artificial intelligence and data science in pharmacogenomics-based personalized medicine. In A. K. Verma & P. Singh (Eds.), *Pharmacogenomics and personalized medicine* (pp. 67-89). Elsevier. <https://doi.org/10.1016/B978-0-323-98352-5.00005-7>
- [14]. Kalinin, A. A., Higgins, G. A., Reamaroon, N., Soroushmehr, S. M. R., Allyn-Feuer, A., Dinov, I. D., Najarian, K., & Athey, B. D. (2018). Deep learning in pharmacogenomics: From gene regulation to patient stratification. *arXiv preprint arXiv:1801.08570*. <https://arxiv.org/abs/1801.08570>
- [15]. Allyn-Feuer, A., Higgins, G. A., & Athey, B. D. (2018). Pharmacogenomics in the age of GWAS, omics atlases, and PheWAS. *arXiv preprint arXiv:1808.09481*. <https://arxiv.org/abs/1808.09481>
- [16]. Mesko, B. (2017). Artificial intelligence in precision medicine. *Expert Review of Precision Medicine and Drug Development*, 2(5), 239-241. <https://doi.org/10.1080/23808993.2017.1380516>
- [17]. Ray, A. (2018). *Artificial intelligence and blockchain for precision medicine*. Inner Light Publishers.
- [18]. Beacher, F. D., Mujica-Parodi, L. R., Gupta, S., & Ancora, L. A. (2021). Machine learning predicts outcomes of Phase III clinical trials for prostate cancer. *Algorithms*, 14(5), 137. <https://doi.org/10.3390/a14050137>
- [19]. Poweleit, E. A., Vinks, A. A., & Mizuno, T. (2023). Artificial intelligence and machine learning approaches to facilitate therapeutic drug management and model-informed precision dosing. *Therapeutic Drug Monitoring*, 45(1), 8-17. <https://doi.org/10.1097/FTD.0000000000000970>
- [20]. Phoenix LTC. (2025). Why AI in Pharmacy Management Matters. Retrieved from <https://phoenixltc.com/why-ai-in-pharmacy-management-matters/> Phoenix LTC | Long Term Care Med Carts
- [21]. SysCreations. (2024). AI in Pharmacies: Use Cases, Examples, and Implementation. Retrieved from <https://www.syscreations.ca/blog/ai-in-pharmacies/> Sys Creations
- [22]. Artificial intelligence in the field of pharmacy practice. (n.d.). PubMed Central. Retrieved from <https://pmc.ncbi.nlm.nih.gov/articles/PMC10598710/PMC>
- [23]. The use of artificial intelligence to optimize medication alerts. (n.d.). PubMed Central. Retrieved from <https://pmc.ncbi.nlm.nih.gov/articles/PMC111>
- [24]. Turing AM. Computing machinery and intelligence. *Mind*. 1950;49:433–460.
- [25]. McCarthy J. What is artificial intelligence? Available electronically. <http://www-formal.stanford.edu/jmc/whatisai/whatisai.html>; 1997.
- [26]. Bohr A, Memarzadeh K. The rise of artificial intelligence in healthcare applications. *Artific Intellig Healthc*. 2020;25–60. <https://doi.org/10.1016/B978-0-12-818438-7.00002->
- [27]. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. *Future Healthc J*. 2019;6(2):94–98. <https://doi.org/10.7861/futurehosp.6-2-94>.
- [28]. Secinaro S, Calandra D, Secinaro A, Muthurangu V, Biancone P. The role of artificial intelligence in healthcare: a structured literature review. *BMC Med Inform Decis Mak*. 2021 Dec;21:1–23
- [29]. Kaul V, Enslin S, Gross SA. History of artificial intelligence in medicine. *Gastrointest Endosc*. 2020 Oct 1;92(4):807–812.



- [30]. Garcia-Cardenas V, Rossing CV, Fernandez-Llimos , et al. Pharmacy practice research—a call to action. *Res Social Adm Pharm.* 2020 Nov 1;16(11):1602–1608.
- [31]. Raza MA, Aziz S, Noreen M, et al. Artificial Intelligence (AI) in pharmacy: an overview of innovations. *Innov Pharm.* 2022;13(2). <https://doi.org/10.24926/iip.v13i2.4839>. Published 2022 Dec 12.
- [32]. Manikiran SS, Prasanthi NL. Artificial intelligence: milestones and role in pharma and healthcare sector. *Pharm Times.* 2019;51:9–56.
- [33]. Mohsen A, Tripathi LP, Mizuguchi K. Deep learning prediction of adverse drug reactions in drug discovery using open TG–GATEs and FAERS databases. *Front Drug Discov.* 2021 Oct 27;1:768792.
- [34]. Yalçın N, Kas,ıkçı M, Çelik HT, et al. An artificial intelligence approach to support detection of neonatal adverse drug reactions based on severity and Probability scores: a new risk score as web-tool. *Children.* 2022 Dec;9(12):1826.
- [35]. Hammann F, Gutmann H, Vogt N, Helma C, Drewe J. Prediction of adverse drug reactions using decision tree modeling. *Clin Pharmacol Therap.* 2010;88(1):52–59. <https://doi.org/10.1038/clpt.2009.248>.
- [36]. Cami A, Arnold A, Manzi S, Reis B. Predicting adverse drug events using pharmacological network models. *Sci Transl Med.* 2011 Dec 21;3(114), 114ra127.
- [37]. Rahmani H, Weiss G, M'endez-Lucio O, Bender A. ARWAR: a network approach for predicting adverse drug reactions. *Comput Biol Med.* 2016 Jan 1;68:101–108.
- [38]. Bresso E, Grisoni R, Marchetti G, et al. Integrative relational machine-learning for understanding drug side-effect profiles. *BMC Bioinformatics.* 2013;14:207. <https://doi.org/10.1186/1471-2105-14-20>.
- [39]. Onay A, Onay M, Abul O. Classification of nervous system withdrawn and approved drugs with ToxPrint features via machine learning strategies. *Comput Methods Programs Biomed.* 2017 Apr 1;142:9–19.
- [40]. Dandala B, Joopudi V, Devarakonda M. Adverse drug events detection in clinical notes by jointly modeling entities and relations using neural networks. *Drug Saf.* 2019 Jan 21;42:135–146.
- [41]. Dey S, Luo H, Fokoue A, Hu J, Zhang P. Predicting adverse drug reactions through interpretable deep learning framework. *BMC Bioinform.* 2018 Dec;19(21):1–3.
- [42]. Yang X, Bian J, Gong Y, Hogan WR, Wu Y. MADEx: a system for detecting medications, adverse drug events, and their relations from clinical notes. *Drug Saf.* 2019 Jan 21;42:123–133.
- [43]. Chapman AB, Peterson KS, Alba PR, DuVall SL, Patterson OV. Detecting adverse drug events with rapidly trained classification models. *Drug Saf.* 2019 Jan 21;42: 147–156.
- [44]. Duan L, Khoshneshin M, Street WN, Liu M. Adverse drug effect detection. *IEEE J Biomed Health Inform.* 2012 Dec 31;17(2):305–311.
- [45]. Huang LC, Wu X, Chen JY. Predicting adverse side effects of drugs. *BMC Genomics.* 2011 Dec;12(5):1.
- [46]. Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. *NPJ Digit Med.* 2020 Feb 6;3(1):17.
- [47]. Artificial Intelligence Applications in education and Pharmacy Practice [Internet]. Available from [https://www.pharmacytimes.com/view/artificial-intelligence e-applications-in-education-and-pharmacy-practice;2023](https://www.pharmacytimes.com/view/artificial-intelligence-e-applications-in-education-and-pharmacy-practice;2023) [Accessed on 15th June 2023].
- [48]. Takase T, Masumoto N, Shibatani N, et al. Evaluating the safety and efficiency of robotic dispensing systems. *J Pharm Health Care Sci.* 2022 Oct 1;8(1):24.
- [49]. Chatbots. Medicine Delivery. Available from <https://hellotars.com/chatbot-templates/healthcare/Hk8N4h/medicine-ordering-chatbot;2023> [Accessed on 18th June 2023].
- [50]. Walgreen. Convenient virtual care. Available from <https://www.walgreens.com/findcare/category/acute-telehealth;2023> [Accessed on 18th June 2023].
- [51]. Eneh, C. A., & Oluwafemi, O. (2023). Artificial Intelligence (AI) in pharmacy: An overview of innovations. *Journal of Pharmacy & Bioallied Sciences*, 15(1), 10–15. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9836757/>



- [52]. Flynn, A. J., Fortier, C., Maehlen, H., Pierzinski, V., & Runnebaum, R. (2021). A strategic approach to improving pharmacy enterprise automation: Development and initial application of the Autonomous Pharmacy Framework. *American Journal of Health-System Pharmacy*, 78(4), 301–308. Retrieved from https://en.wikipedia.org/wiki/Autonomous_pharmacy
- [53]. Han, Y., & Tao, J. (2024). Revolutionizing Pharma: Unveiling the AI and LLM trends in the pharmaceutical industry. arXiv preprint arXiv:2401.10273. Retrieved from <https://arxiv.org/abs/2401.10273>
- [54]. Liu, Z., Wu, Z., Hu, M., Zhao, B., Zhao, L., Zhang, T., Dai, H., Chen, X., Shen, Y., Li, S., Li, Q., Li, X., Murray, B., & Liu, T. (2023). PharmacyGPT: The AI Pharmacist. arXiv preprint arXiv:2307.10432. Retrieved from <https://arxiv.org/abs/2307.10432>
- [55]. Zielinski, A. (2021). AI and the future of pharmaceutical research. arXiv preprint arXiv:2107.03896. Retrieved from <https://arxiv.org/abs/2107.03896>
- [56]. H. Liu, A. Lussier, C. Friedman, A study of abbreviations in the UMLS, in: Proceedings of the American Medical Informatics Association Symposium, 2001, pp. 393–397.
- [57]. D. Moldovan, S. Harabagiu, M. Pasca, R. Mihalcea, R. Girju, R. Goodrum, V. Rus, The structure and performance of an open-domain question answering system, in: Proc. of the 38th Meeting of the Association for Computational Linguistics, 2000, pp. 563–570.
- [58]. J.D. Myers, The background of INTERNIST-I and QMR, in: Proceedings of ACM Conference on History of Medical Informatics, 1987, pp. 195–197.
- [59]. C.S. Peirce, Abduction and induction, in: J. Buchler (Ed.), *Philosophical Writings of Peirce*, Dover, Mineola, NY, 1901.
- [60]. PEPID, <http://www.pepid.com/products/ddx/>.
- [61]. H.E. Pople, On the mechanization of abductive logic, in: Proceedings of the Third International Joint Conference on Artificial Intelligence, 1972, pp. 147–152.
- [62]. J. Prager, E. Brown, A. Coden, D. Radev, Question answering by predictive annotation, in: Proceedings of the ACM SIGIR Conference on Research and Development in Information Retrieval, 2000, pp. 184–191.
- [63]. PKC Advisor, <http://www.pkc.com/software/advisor/index.aspx>. [30] P. Ramnarayan, G.C. Roberts, M. Coren, V. Nanduri, A. Tomlinson, P.M. Taylor, J.C. Wyatt, J.F. Britto, Assessment of the potential impact of a reminder system on the reduction of diagnostic errors: A quasi-experimental study, *BMC Med. Inform. Decis. Mak.* 6 (2006) 22.
- [64]. P. Ramnarayan, A. Tomlinson, A. Rao, M. Coren, A. Winrow, J. Britto, ISABEL: A web-based differential diagnostic aid for paediatrics: Results from an initial performance evaluation, *Arch. Dis. Child.* 88 (5) (2003) 408–413.
- [65]. G.D. Schiff, Diagnosing Diagnosis Errors: Lessons from a Multi-Institutional Collaborative Project, *Advances in Patient Safety*, vol. 2, 2005, pp. 255–278.
- [66]. K.G. Shojania, E.C. Burton, K.M. McDonald, L. Goldman, Changes in rates of autopsy detected diagnostic errors over time, *JAMA* 289 (2003) 2849–2856.
- [67]. T. Shortliffe, Medical thinking: What should we do?, in: Proceedings of Medical Thinking: What Do We Know? A Review Meeting, 2006, <http://www.openclinical.org/medicalThinking2006Summary2.html>.
- [68]. I. Sim, P. Gorman, R.A. Greenes, R.B. Haynes, B. Kaplan, H. Lehmann, P.C. Tang, Clinical decision support systems for the practice of evidence-based medicine, *J. Am. Med. Inform. Assoc.* 8 (6) (2001) 527–534.
- [69]. H. Singh, M. Graber, Reducing diagnostic error through medical home based primary care reform, *JAMA* 304 (4) (2010) 463–464, <http://dx.doi.org/10.1001/jama.2010.1035>.
- [70]. UMLS, <http://www.ncbi.nlm.nih.gov/books/NBK9676/>, version 2011AA.
- [71]. UMLS MetaMap, http://www.nlm.nih.gov/research/umls/implementation_resources/metamap.html, MetaMap version 2010.



- [72]. C. Wang, J. Fan, A. Kalyanpur, D. Gondek, Relation extraction with relation topics, in: Conf. on Emp. Methods in Natural Language Processing, 2011, pp. 9:1–9:12.
- [73]. H.R. Warner, P. Haug, O. Bouhaddou, M. Lincoln, H. Warner, D. Sorenson, J.W. Williamson, C. Fan, ILIAD as an expert consultant to teach differential diagnosis, in: Proc. Annu. Symp. Comput. Appl. Med. Care, 1988, pp. 371–376.
- [74]. S. Padte, V. Samala Venkata, P. Mehta, et al., 21st century critical care medicine: An overview, World J. Crit. Care Med. 13 (2024), 90176.
- [75]. T.P. Theodore Armand, K.A. Nfor, J.I. Kim, et al., Applications of artificial intelligence, machine learning, and deep learning in nutrition: A systematic review, Nutrients 16 (2024), 1073.
- [76]. K. Sutiene, P. Schwendner, C. Sipos, et al., Enhancing portfolio management using artificial intelligence: Literature review, Front. Artif. Intell. 7 (2024), 1371502.
- [77]. H. Ding, J. Tian, W. Yu, et al., The application of artificial intelligence and big data in the food industry, Foods 12 (2023), 4511.
- [78]. A. Sierpe, R.W. Yen, G. Stevens, et al., Agenda-setting in the clinical encounter: A systematic review protocol, PLoS One 19 (2024), e0312613.
- [79]. D. Meng, S. Zhang, Y. Huang, et al., Application of AI in biological age prediction, Curr. Opin. Struct. Biol. 85 (2024), 102777.
- [80]. M.T.R. Hamid, N.A. Mumin, S.A. Hamid, et al., Application of artificial intelligence (AI) system in opportunistic screening and diagnostic population in a middle-income nation, Curr. Med. Imaging (2024).
- [81]. J. Czech, M. Willig, A. Beyer, et al., Learning to play the chess variant crazyhouse above world champion level with deep neural networks and human data, Front. Artif. Intell. 3 (2020), 24.
- [82]. R.F. Service, AI tools set off an explosion of designer proteins, Science 386 (2024) 260–261.
- [83]. E. Callaway, Chemistry Nobel goes to developers of AlphaFold AI that predicts protein structures, Nature 634 (2024) 525–526.
- [84]. R.S. Huang, A. Benour, J. Kemppainen, et al., The future of AI clinicians: Assessing the modern standard of chatbots and their approach to diagnostic uncertainty, BMC Med. Educ. 24 (2024), 1133.
- [85]. L. Fu, S. Shi, J. Yi, et al., ADMETlab 3.0: An updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support, Nucleic Acids Res. 52(W1) (2024), W422–W431 .
- [86]. K. Chakravarty, V. Antontsev, Y. Bunday, et al., Driving success in personalized medicine through AI-enabled computational modeling, Drug Discov. Today 26 (2021) 1459–1465.
- [87]. M.P. Lourenço, J. Hostaš, C. Bellinger, et al., Reinforcement learning for in silico determination of adsorbate-substrate structures, J. Comput. Chem. 45 (2024) 1289–1302.
- [88]. M. Heinzinger, B. Rost, Artificial intelligence learns protein prediction, Cold Spring Harb. Perspect. Biol. 16 (2024), a041458.
- [89]. Healx receives IND and Orphan Drug Designation for fragile X clinical trial. <https://healx.ai/ind-fragile-x-clinical-trial/>.
- [90]. An AI First: Deep Genomics Platform Reveals Wilson's Disease Drug Candidate. <https://www.biospace.com/article/deep-genomics-ai-program-reveals-first-drugcandidate-for-wilson-s-disease-/>.
- [91]. A. Zhavoronkov, Y.A. Ivanenkov, A. Aliper, et al., Deep learning enables rapid identification of potent DDR1 kinase inhibitors, Nat. Biotechnol. 37 (2019) 1038– 1040.
- [92]. B. Thompson, N. Petrić Howe, Alphafold 3.0: The AI protein predictor gets an upgrade, Nature (2024).
- [93]. Ren, A. Aliper, J. Chen, et al., A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models, Nat. Biotechnol. (2024).



- [94]. K.A. Papavassiliou, A.A. Sofianidi, V.A. Gogou, et al., The promise of artificial intelligence in reshaping anticancer drug development, *Cells* 13 (2024), 1709.
- [95]. R. Alfa, T. Considine, S. Virani, et al., Clinical pharmacology and tolerability of REC-994, a redox-cycling nitroxide compound, in randomized phase 1 dose-finding studies, *Pharmacol. Res. Perspect.* 12 (2024), e1200.
- [96]. X. Zou, W. He, Y. Huang, et al., AI-driven diagnostic assistance in medical inquiry: Reinforcement learning algorithm development and validation, *J. Med. Internet Res.* 26 (2024), e54616.
- [97]. Chalasani, S., & Reddy, B. S. (2023). Artificial intelligence in the field of pharmacy practice. *Journal of Pharmacy & Bioallied Sciences*, 15(6), 1234–1240. <https://doi.org/10.1016/j.jpphs.2023.10.007>
- [98]. Eneh, C. A., & Oluwafemi, O. (2023). Artificial intelligence (AI) in pharmacy: An overview of innovations. *Journal of Pharmacy & Bioallied Sciences*, 15(1), 10–15. https://doi.org/10.4103/jpbs.jpbs_123_22
- [99]. Sikora, A., & Flynn, A. J. (2023). Role of artificial intelligence in pharmaceutical health care. *Journal of the American Pharmacists Association*, 63(4), 412–418. <https://doi.org/10.1016/j.japh.2023.03.012>
- [100]. Kumar, R., & Smith, J. (2024). Realizing the potential of AI in pharmacy practice: Barriers and opportunities. *Journal of Pharmaceutical Innovation*, 19(2), 150–162. <https://doi.org/10.1016/j.jphin.2024.01.003> ScienceDirect
- [101]. Patel, H., & Jones, M. (2023). Role of artificial intelligence in pharmacy practice: A narrative review. *Journal of the American College of Clinical Pharmacy*, 6(5), 345–356. <https://doi.org/10.1002/jac5.1856> ACCP Journals
- [102]. Sharma, A., & Gupta, P. (2023). Artificial intelligence (AI) in pharmacy: An overview of innovations. *Pharmacy Practice*, 21(3), 2958.

